Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025
Several big-selling branded drugs are anticipated to become the targets of biannual generic listings in 2025, Jiho has learned. In the field of diabetes, copycats of the SGLT2 inhibitor Forxiga (dapagliflozin) are likely to reach the market, following the generic…
To read the full story
Related Article
- Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
BUSINESS
- 3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
- MSA Drug NPC-29 Set to Enter PIII This Month: Nobelpharma CEO
February 5, 2026
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…